SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The High Cost of Cancer Drugs and What We Can Do About It
10 references·11 citing·43 second hop
The High Cost of Cancer Drugs and What We Can Do About It (2012)The High Cost of Cancer Drugs and What We…Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs (2010)Trends in Risks Associated Wi…Medical Bankruptcy in the United States, 2007: Results of a National Study (2009)Medical Bankruptcy in the Uni…Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)Limits on Medicare's Ability …Economics of New Oncology Drug Development (2007)Economics of New Oncology Dru…Cost of Cancer Care: Issues and Implications (2007)Cost of Cancer Care: Issues a…Calculating QALYs, comparing QALY and DALY calculations (2006)Calculating QALYs, comparing …The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine (1996)The role of cost-effectivenes…The Role of Cost-effectiveness Analysis in Health and Medicine (1996)The Role of Cost-effectivenes…EuroQol - a new facility for the measurement of health-related quality of life (1990)EuroQol - a new facility for …A general health policy model: update and applications. (1988)A general health policy model…Enabling Safe and Sustainable Medical Deliveries by Connected Autonomous Freight Vehicles Operating within Dangerous Goods Regulations (2022)Enabling Safe and Sustainable…Barriers in access to oncology drugs — a global crisis (2022)Barriers in access to oncolog…Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma (2021)Cost-effectiveness of Atezoli…The high cost of prescription drugs: causes and solutions (2020)The high cost of prescription…Health services costs for cancer care in Australia: Estimates from the 45 and Up Study (2018)Health services costs for can…Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund (2017)Do patient access schemes for…Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure (2016)Steady Increase In Prices For…Advanced therapy medicinal products: current and future perspectives (2016)Advanced therapy medicinal pr…Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions? (2015)Why Are Cancer Drugs So Expen…Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework (2014)Value-Based Reimbursement Dec…Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs? (2014)Do Value Thresholds for Oncol…Free for All? Lessons from the RAND Health Insurance Experiment (1995)Income, Poverty, and Health Insurance Coverage In The United States: 2006 (2007)Protecting Households From Catastrophic Health Spending (2007)Delivering affordable cancer care in high-income countries (2011)Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer Diagnosis (2013)The development of a financial toxicity patient‐reported outcome in cancer: The COST measure (2014)The price of innovation: new estimates of drug development costs (2003)Can the pharmaceutical industry reduce attrition rates? (2004)Deconstructing the Drug Development Process: The New Face of Innovation (2010)Challenges and opportunities of drug repositioning (2013)Killer Acquisitions (2020)Cost of innovation in the pharmaceutical industry (1991)Estimating The Cost Of New Drug Development: Is It Really $802 Million? (2006)Incentives for orphan drug research and development in the United States (2008)Commercializing biomedical research through securitization techniques (2012)Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study (2018)Cost-Effectiveness in Health and Medicine (1996)Modeling Valuations for EuroQol Health States (1997)Methods for the Economic Evaluation of Health Care Programmes (2005)The Economic Analysis of Prevention in Mental Health Programs (2011)Predicting the cost-effectiveness of total hip and knee replacement (2013)An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations (2021)Prospect Theory: An Analysis of Decision under Risk (1979)Prospect theory: An analysis of decision under risk (1988)Health Care Disparities (2003)Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006 (2010)Patient-Oncologist Cost Communication, Financial Distress, and Medication Adherence (2014)Methods for measuring financial toxicity after cancer diagnosis and treatment: a systematic review and its implications (2019)Health status: types of validity and the index of well-being. (1976)The Sickness Impact Profile: Validation of a Health Status Measure (1976)The Sickness Impact Profile: Development and Final Revision of a Health Status Measure (1981)Setting Health Care Priorities in Oregon (1991)A review of the use of health status measures in economic evaluation. (1999)US Norms for Six Generic Health-Related Quality-of-Life Indexes From the National Health Measurement Study (2007)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)HALYs and QALYs and DALYs, Oh My: Similarities and Differences in Summary Measures of Population Health (2002)Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge? (2004)Cancer Drugs in the United States: Justum Pretium—The Just Price (2013)Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity (2014)Five Years of Cancer Drug Approvals (2015)EuroQol: the current state of play (1996)EQ-SD: a measure of health status from the EuroQol Group (2001)Recommendations for Reporting Cost-effectiveness Analyses (1996)
this work references cited by second hop

References

  • 1990EuroQol - a new facility for the measurement of health-related quality of life15,736 cited
  • 1996The Role of Cost-effectiveness Analysis in Health and Medicine1,168 cited
  • 1996The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine967 cited
  • 2010Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs847 cited
  • 2009Medical Bankruptcy in the United States, 2007: Results of a National Study806 cited
  • 2006Calculating QALYs, comparing QALY and DALY calculations574 cited
  • 1988A general health policy model: update and applications.473 cited
  • 2009Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs391 cited
  • 2007Cost of Cancer Care: Issues and Implications353 cited
  • 2007Economics of New Oncology Drug Development348 cited

Cited by

  • 2016Advanced therapy medicinal products: current and future perspectives171 cited
  • 2017Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund162 cited
  • 2020The high cost of prescription drugs: causes and solutions161 cited
  • 2018Health services costs for cancer care in Australia: Estimates from the 45 and Up Study139 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

  • 2022Barriers in access to oncology drugs — a global crisis139 cited
  • 2015Why Are Cancer Drugs So Expensive in the United States, and What Are the Solutions?115 cited
  • 2014Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework99 cited
  • 2021Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma80 cited
  • 2016Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure75 cited
  • 2014Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs?73 cited
  • 2022Enabling Safe and Sustainable Medical Deliveries by Connected Autonomous Freight Vehicles Operating within Dangerous Goods Regulations10 cited